Drug name - Wakix

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8207197 HARMONY Monohydrochloride salt of 1-[3-[3-(4-chlorophenyl) propoxy] propyl] -piperidine
Feb, 2029

(6 years from now)

CN101155793B HARMONY 1-[3-[3-(4) Propoxy] Propyl Group]-Pyrazine And One Hydrochloride
Feb, 2026

(3 years from now)

CN101155793A HARMONY Monohydrochloride Of 1-[3-[3-(4-Chlorophenyl)Propoxy]Propyl]-Piperidine
Feb, 2026

(3 years from now)

IN247019B HARMONY A Process For The Production Of Crystalline Monohydrochloride Salt Of 1- [3-[3-(4-Chlorophenyl) Propoxy] Propyl] - Piperidine
Feb, 2026

(3 years from now)

IN200703493P4 HARMONY Monohydrochloride Salt Of 1- (Chlorophenyl) Propoxy Propyl - Piperidine
Feb, 2026

(3 years from now)

EP1690858A1 HARMONY Monohydrochloride Salt Of 1-[3-[3-(4-Chlorophenyl)Propoxy]Propyl]-Piperidine
Feb, 2025

(2 years from now)

EP1690858B1 HARMONY Monohydrochloride Salt Of 1-[3-[3-(4-Chlorophenyl)Propoxy]Propyl]-Piperidine
Feb, 2025

(2 years from now)

EP1846384B1 HARMONY Monohydrochloride Salt Of 1-[3-[3-(4-Chlorophenyl)Propoxy]Propyl]-Piperidine
Feb, 2026

(3 years from now)

EP1846384A1 HARMONY Monohydrochloride Salt Of 1-[3-[3-(4-Chlorophenyl)Propoxy]Propyl]-Piperidine
Feb, 2026

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8354430 HARMONY Monohydrochloride salt of 1-[3-[3-(4-chlorophenyl) propoxy]propyl]-piperidine Feb, 2026

(3 years from now)

US8486947 HARMONY Treatment of Parkinson's disease, obstructive sleep apnea, dementia with Lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3-receptor ligands Sep, 2029

(6 years from now)

Drugs and Companies using PITOLISANT HYDROCHLORIDE ingredient

Treatment: Method of treating excessive daytime sleepiness in patients with narcolepsy; method of treating cataplexy in patients with narcolepsy

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 4.45MG BASE TABLET;ORAL Prescription
EQ 17.8MG BASE TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.